NHS England has started offering fampridine, a prescription medicine designed specifically to improve walking ability in eligible adults with multiple sclerosis (MS). The drug represents the first NHS-funded treatment targeting mobility rather than disease progression itself. Around 5,000 patients are expected to benefit in the first year, though treatment continues only if it demonstrates clear improvement.

How Does Fampridine Help People With MS Walk Better?

Fampridine works by helping nerve signals travel more effectively through damaged areas of the spinal cord and brain affected by MS. Clinical evidence found that about 43% of patients walked faster after taking the medication. Beyond speed, real-world studies and expert reviews reported that people who respond to treatment may also notice improvements in endurance, balance, and overall quality of life alongside better walking ability.

The medicine does not cure MS or stop the disease from progressing. Instead, it addresses a specific symptom that affects many people's daily independence. For eligible patients, this distinction matters: fampridine targets the practical challenge of mobility without claiming to reverse underlying nerve damage.

Who Can Receive Fampridine Through the NHS?

The NHS commissioning policy recommends fampridine for adults with an Expanded Disability Status Scale (EDSS) score of 4 to 7, which reflects moderate to significant walking difficulty. Patients receive an initial trial period of 2 to 4 weeks, after which doctors reassess whether the medicine is working. If there is no meaningful improvement in walking ability, treatment is discontinued.

This careful assessment approach reflects an important reality: not everyone responds to fampridine. In real-world healthcare settings, 59% of patients showed a positive response to treatment, meaning roughly 4 in 10 eligible people may not benefit. Doctors check whether the medicine is working before deciding if treatment should continue, ensuring resources go to those who actually experience improvement.

Steps to Maximize Walking Improvement With MS Treatment

Fampridine works best as part of a broader approach to mobility. Experts recommend combining medication with supportive therapies to help maintain and build walking ability:

• Physical Therapy: Structured rehabilitation strengthens muscles and improves movement patterns, complementing the effects of fampridine on nerve signaling.
• Regular Exercise: Consistent activity builds balance and endurance, helping patients sustain improvements in walking speed and stability over time.
• Walking Aids When Needed: Canes, walkers, or other assistive devices improve safety and reduce fall risk, allowing patients to stay active with greater confidence.

This combination approach addresses why medicine alone is not enough. Fampridine improves nerve signal transmission, but physical conditioning and practical support systems help patients translate that improvement into real-world independence for everyday activities like shopping, climbing stairs, or walking longer distances.

What Safety Monitoring Do Patients Undergo?

Fampridine was generally well tolerated during clinical studies, though the medication does require monitoring. Doctors typically assess walking ability after about 2 to 4 weeks of treatment to determine if the drug is working. Patients can continue physiotherapy and other supportive therapies while taking fampridine, as experts recommend using the medication alongside rehabilitation rather than as a replacement.

The NHS rollout represents a significant shift in MS treatment philosophy. Rather than focusing solely on slowing disease progression, fampridine acknowledges that improving daily function and independence matters deeply to people living with MS. For the thousands of eligible patients who respond to treatment, the ability to walk faster and more steadily can make everyday life substantially easier and support greater confidence while moving.